Richard Buchta
Direttore/Membro del Consiglio presso BERONI GROUP LIMITED
Profilo
Richard Buchta is currently a Director at Opal Biosciences Ltd., an Independent Non-Executive Director at Beroni Group Ltd., and a Director at Formulytica Pty Ltd.
He previously worked as a Senior Vice President-Research & Development at Vyome Therapeutics, Inc. Buchta received his undergraduate degree from Monash University, an MBA from Deakin University, and doctorates from the Weizmann Institute of Science and the University of Trieste.
Posizioni attive di Richard Buchta
| Società | Posizione | Inizio |
|---|---|---|
| BERONI GROUP LIMITED | Direttore/Membro del Consiglio | 01/07/2020 |
Formulytica Pty Ltd.
 Formulytica Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Opal Biosciences Ltd., Formulytica Pty Ltd. is a specialty research organization that provides regulatory solutions, training in formulation and analytical techniques, and troubleshooting formulation and analytical methods. The company is based in Mulgrave, Australia. The Australian company specializes in contract formulation development services, analytical method development and validation, new product development, and the analytical science of semi-solid formulations. Formulytica was acquired by Opal Biosciences Ltd. on May 05, 2021. | Direttore/Membro del Consiglio | - |
Opal Biosciences Ltd.
 Opal Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Opal Biosciences Ltd. develops antimicrobial and anti-infective products. The company was founded in and is headquartered in South Melbourne, Australia. | Direttore/Membro del Consiglio | 05/05/2021 |
Precedenti posizioni note di Richard Buchta
| Società | Posizione | Fine |
|---|---|---|
Vyome Therapeutics, Inc.
 Vyome Therapeutics, Inc. BiotechnologyHealth Technology Vyome Therapeutics, Inc. develops research-based dermatology pharmaceutical solutions. It also develops drugs for antibiotics-resistant acne and other pathogens through a pipeline of antibiotics that retard resistance development. The company was founded by Rajesh Sudhir Gokhale, Rajeev Mantri, Venkateswarlu Nelabhotla, and Shiladitya Sengupta in August 2010 and is headquartered in Princeton, NJ. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Richard Buchta
| Monash University | Undergraduate Degree |
| Deakin University | Masters Business Admin |
| Weizmann Institute of Science | Doctorate Degree |
| University of Trieste | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BERONI GROUP LIMITED | Health Technology |
| Aziende private | 3 |
|---|---|
Vyome Therapeutics, Inc.
Vyome Therapeutics, Inc. BiotechnologyHealth Technology Vyome Therapeutics, Inc. develops research-based dermatology pharmaceutical solutions. It also develops drugs for antibiotics-resistant acne and other pathogens through a pipeline of antibiotics that retard resistance development. The company was founded by Rajesh Sudhir Gokhale, Rajeev Mantri, Venkateswarlu Nelabhotla, and Shiladitya Sengupta in August 2010 and is headquartered in Princeton, NJ. | Health Technology |
Opal Biosciences Ltd.
Opal Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Opal Biosciences Ltd. develops antimicrobial and anti-infective products. The company was founded in and is headquartered in South Melbourne, Australia. | Health Technology |
Formulytica Pty Ltd.
Formulytica Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Opal Biosciences Ltd., Formulytica Pty Ltd. is a specialty research organization that provides regulatory solutions, training in formulation and analytical techniques, and troubleshooting formulation and analytical methods. The company is based in Mulgrave, Australia. The Australian company specializes in contract formulation development services, analytical method development and validation, new product development, and the analytical science of semi-solid formulations. Formulytica was acquired by Opal Biosciences Ltd. on May 05, 2021. | Commercial Services |
- Borsa valori
- Insiders
- Richard Buchta
